Memantin 1 A Pharma

Memantine, the active ingredient in Memantin 1 A Pharma, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantin 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is used in the treatment of Alzheimer’s disease, targeting the glutamatergic pathway associated with cognitive decline.

- Moderate to severe Alzheimer’s disease: improves cognition and functional abilities in patients with established disease. - Cognitive impairment in Alzheimer’s disease: may help maintain daily living activities. - Functional decline in Alzheimer’s disease: supports slower progression of daily functional loss.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Nausea

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or elevated liver enzymes - Seizures - Suicidal thoughts or behavior - Neuroleptic malignant‑like syndrome - Persistent hallucinations or psychosis

Memantin 1 A Pharma requires careful patient assessment and monitoring.

- Renal impairment: evaluate renal function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes during therapy. - History of seizures: use with caution and observe for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use to reduce risk of neurotoxicity. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Memantin 1 A Pharma may interact with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists (e.g., dextromethorphan): risk of excessive inhibition. - Strong alkaline antacids (e.g., magnesium hydroxide): may reduce memantine absorption.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Diuretics (e.g., furosemide): can raise plasma memantine concentrations. - Carbamazepine: may lower memantine levels, reducing efficacy.